While HIV medications receive much attention for the treatment of HIV infection, less attention has focused on the prophylaxis indications. In 2017, the Center for Disease Control and Prevention (CDC) updated their guidelines on the indications for the HIV medications tenofovir disoproxil fumarate (TDF) and emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine, FTC) for pre-exposure prophylaxis (PrEP). The trade name for the combination medication is Truvada. These daily medications are taken by people at risk for HIV to prevent HIV. This Guideline Review succinctly summarizes the 77-page CDC document into the key pearls for emergency physicians.
Guideline Review: Pre-Exposure Prophylaxis (PrEP)
Important reference number: National Clinicians Consultation Center (U.S.) – 855-448-7737
Author information
The post Guideline Review: Pre-exposure prophylaxis (PrEP) for HIV prevention appeared first on ALiEM.
